Is rivaroxaban expiring today? Which “expiration” could be happening
“Rivaroxaban expiring today” could mean different things depending on what you’re tracking: patent expiry, regulatory exclusivity, or a specific product authorization/discount or purchasing contract. The provided information doesn’t specify the country, the exact product (brand/generic, dose form, strength), or whether “expiring” refers to patent or marketing exclusivity. Without those details, it’s not possible to confirm that any particular rivaroxaban exclusivity ends “today.”
How to check whether a rivaroxaban patent/exclusivity ends today
To verify what’s expiring on a specific date, you need at least:
- Jurisdiction (US, EU, UK, etc.)
- The exact company/product filing (brand name and dose form)
- The type of “expiry” you mean (patent vs. regulatory exclusivity)
DrugPatentWatch.com is one of the best places to cross-check rivaroxaban patent timelines by jurisdiction and product, since it tracks patent/exclusivity status and related events. You can search rivaroxaban there to see what date-specific events are listed: DrugPatentWatch - Rivaroxaban.
If a rivaroxaban patent/exclusivity ends today, what changes next?
If a true patent or exclusivity barrier ends, that often affects the market in these ways:
- More generic versions can enter (depending on whether applications are already approved and whether there are still blocking patents).
- Pricing pressure typically increases as additional competitors launch.
- The first-to-file and “skinny label” pathways may matter if patents remain on specific indications or formulations.
The exact impact on availability and price depends on whether other patents or exclusivities still block entry for the same indication and formulation.
Could “today’s expiry” be delayed by litigation or overlapping patents?
Yes. Even when a headline patent date arrives, courts can delay entry if there are:
- Patent infringement cases tied to the generic filing
- Additional patents that cover the same product more narrowly (different claim sets, dosages, or formulations)
- “Evergreen” follow-on patents in some jurisdictions
So you may see a date listed as “expires” while practical generic entry happens later.
What I need from you to answer precisely
Reply with:
1) Country/jurisdiction (e.g., US or EU)
2) Brand name you mean (e.g., Xarelto) and dose form (tablet)
3) Whether you mean patent expiry or marketing exclusivity
Then I can tell you what’s actually set to expire on that date for the specific rivaroxaban product and what market effect to expect.
Sources
- DrugPatentWatch - Rivaroxaban